BENNETT C FRANK 4/A

What Happened

• Bennett C. Frank, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), filed an amended Form 4 clarifying that no net disposition occurred. The amended report shows an entry of 0 shares @ $0.00 (code J — other acquisition/disposition) for the Period of Report 2026-02-02.
• A prior Form 4 (filed Feb 4, 2026) had reported the sale of 20,000 shares and the exercise of 65,089 stock options; those transactions were executed in error and were reversed on Feb 12, 2026. As of Feb 12, 2026, Mr. Frank beneficially owns 100,293 shares.

Key Details

• Reported/period date: 2026-02-02 (amended filing date: 2026-02-13).
• Amended transaction in form: 0 shares disposed @ $0.00 (transaction code J).
• Originally reported (in error): sale of 20,000 shares and exercise of 65,089 options; both reversed on 2026-02-12 per footnote.
• Shares owned after the reversal: 100,293 beneficially owned.
• Filing status: Amended Form 4 — correction of previously reported/error transactions. No proceeds or new holdings resulted from this amended filing.

Context

• The filing documents a correction of administrative/error trades rather than a deliberate buy or sell signal. For retail investors, reversals of erroneous exercises/sales typically reflect operational mistakes and should not be interpreted as insider sentiment or planned trading. Options exercises and subsequent sales (if they had occurred) can be routine and tax/compensation driven; here, however, the exercise/sale were reversed, leaving no net change.